• eSTRAND RNA QC™ uses nanopore-based direct RNA sequencing to offer multi-attribute RNA characterization.
• Using direct RNA sequencing, eSTRAND RNA QC reads full-length RNA without requiring reverse transcription or translation.
• eSTRAND RNA QC simultaneously measures RNA identity, poly(A) tail length, capping efficiency, fragmentation hotspots, and double-stranded RNA.

Eclipse Bioinnovations, Inc. (Eclipsebio), the leader in sequencing-based analytics and AI-enabled design for RNA therapeutics, today announced the launch of eSTRAND RNA QC™, a multi-attribute nanopore-based RNA characterization assay.

Traditional analytical tools provide limited information on RNA characterization, making it difficult for drug developers to determine the best manufacturing selections for an effective therapeutic. eSTRAND RNA QC uses nanopore-based direct RNA sequencing to overcome this challenge. Direct RNA sequencing reads full-length RNA without requiring reverse transcription or translation, providing clear, actionable insights into RNA characterization.

“Low-resolution, single-dimensional insights from traditional characterization assays are not sufficient for today’s drug development standards,” said Eclipsebio Co-Founder and CEO Peter Chu, Ph.D. “eSTRAND RNA QC provides essential multi-attribute testing to provide partners the full scope of their RNA therapeutic quality.”

With direct RNA sequencing, eSTRAND RNA QC can measure multiple critical quality attributes in a single run, including RNA identity, poly(A) tail length, capping efficiency, fragmentation hotspots, and double-stranded RNA. These simultaneous measurements save drug developers time, helping them get their therapeutic to clinic faster.

Source – PR Newswire